Page 832 - ACCCN's Critical Care Nursing

I N D E X 809

in haemostasis system see haemostasis psychosocial care, lung transplantation and 374 handheld technologies 48–49
system PTA scale see posttraumatic amnesia scale telehealth initiatives 49
in immune system see immune system PTCA see percutaneous transluminal coronary Quality in Australian Health Care Study
in liver see liver angioplasty (QAHCS) 42–43
maternal-fetal interface see maternal-fetal PTSD see posttraumatic stress disorder quality monitoring 42–49
interface PTSS see posttraumatic stress symptoms quality of life 85
in renal system see renal system PTSS-10 see Post-Traumatic Stress Syndrome quality use of medicines (QUM) 42
in respiratory system see respiratory system 10-Questions Inventory quantitative research 11
in white blood count see white cell count publication, ethics in 95 QUM see quality use of medicines
placenta accreta 722b puerperal psychosis 731
placenta praevia 721–722, 722b puerperium, psychology of 738
placenta role 715–716 pulmonary artery catheter (PAC) 200, 201f R
placental abruption 721 shock and 542 RAAS see renin-angiotensin-aldosterone system
pneumonia and 730 pulmonary artery occlusion pressure radiological materials 606
postpartum haemorrhage 721 (PAOP) 201–202 Ramsay Sedation Scale 141t
preeclampsia 716–721, 718b–719b, 718t pulmonary artery pressure (PAP) rapid eye movement (REM) 145–146
Rhesus disease prevention 733, 735t monitoring 200–201, 201f rapid response systems (RRS) 50–52
SCA and 669 waveform 202f afferent limb of 50–51
seatbelt position and 729, 729f pulmonary aspiration Australian Commission on Safety and Quality
trauma in 729–730 assessment of 512–513 in Health Care on 50
utero-placental gas exchange 716 prevention of 512 efferent limb of 51–52
preload 185–186, 199–202 pulmonary assessment, for CHF 231 elements of 50t
CVP monitoring 200 pulmonary capillary wedge pressure research on 52t
LAP monitoring 202 (PCWP) 186, 199–200, 296 rapid response team (RRT) 51
PAP monitoring 200–201, 201f monitoring of 201–202, 202f RAS see reticular activation system
PCWP monitoring 201–202, 202f pulmonary circulation 328, 328f–329f RASS see Richmond Agitation-Sedation Scale
prerenal acute renal failure 483–484 pulmonary contusion 636 RCA see right coronary artery; root cause analysis
preschool children, developmental pulmonary dynamic hyperinflation RCM see restrictive cardiomyopathy
considerations in 684–685 (PDH) 372–373, 372f, 788 RCSQ see Richards Campbell Sleep
pressure double-lumen ETT position for 372, 372f Questionnaire
area care 112–113 pulmonary embolism (PE) 114, 345, 367–369 real timing, in balloon deflation 304, 305b
control 396 assessment and diagnostics of 368 REBs see Research and Ethical Boards
sores clinical manifestations of 368 recipient 788
monitoring 113, 114t collaborative practice for 368–369 recombinant human activated protein C,
risk assessment 112–113, 112t–113t medications 369–374, 369t for septic shock 554
treatment of 113 risk factors for 368t recruitment manoeuvres (RMs) 401
vs time scalar 398–399, 399f pulmonary oedema 334–335, 345 red blood cell, administration guidelines,
ulcer 787 pathophysiology of 230, 231f hypovolaemic shock and 545t
pressure support ventilation (PSV) 392t, 393, pulmonary vascular resistance (PVR) 202–203 redback spider bite 606–607
396, 397t pulmonary volumes and capacities 330–331, reentry 252
pressure-controlled ventilation 787 330f reentry tachycardia 257–258, 258f
pressure-regulated volume control (PRVC) 397t, alveolar ventilation 331 refeeding syndrome 788
398, 787 pulmonic circulations 183f reflex(es)
pressure-volume loops 399–401, 400f–401f pulse, assessment of 190–191 controls 329f
primary graft dysfunction (PGD) 371 pulse contour cardiac output (PiCCO) 296 corneal 434
principles of practice 105, 106t pulse oximetry 339–340, 340f, 788 oropharyngeal 434
Prismaflex CRRT machine 499f research vignette 348b–349b refractory hypoxaemia management 401–402
privacy 788 pulse waveforms, ICP monitoring 437–438, ECMO 401–402
Privacy Act 1993 93–94 438f HFOV 401
privacy and confidentiality, health research pulse-induced contour 203–204, 204f nitric oxide 402
information and 93–95 pulseless ventricular tachycardia, ALS and recruitment manoeuvres 401
procoagulation, MODS and 565–566 663 regeneration, SCI and 462
professional organisations 5–6 pupil assessment 433 rehabilitation, in ICU 66
Prognostic Inflammatory Nutrition Index purchasing equipment 22–23 rejection 788
(PINI) 509 Purkinje fibers 184–185 of heart transplantation
prosthetic valves 294, 295f PVR see pulmonary vascular resistance acute 313, 313t, 318t
proteins, acute phase 783 hyperacute 313
protocol 788 relative humidity 389
proton pump inhibitors (PPIs) 516 Q religious beliefs and practices 170–171, 170t
PRVC see pressure-regulated volume control QAHCS see Quality in Australian Health Care recognising needs 171, 171t
pseudoaneurysm 244, 244f Study REM see rapid eye movement
PSG see polysomnography QI see quality improvement remote critical care management (eICU) 49
PSI see Pneumonia Severity Index QRS complex 194–195, 194f renal dialysis 482–483
PSV see pressure support ventilation Q-T interval 194, 194f history of 488–491, 488f, 489t
PSVT see paroxysmal supraventricular monitoring of, research vignette 287b nursing and 489, 490f
tachycardia qualitative research 11 renal replacement therapy refinement
psychological care quality improvement (QI) 42 and 490–491
anxiety 133–136 care bundles 43, 44t see also renal replacement therapy
case study 149b–150b case study 53b renal dysfunction
delirium 136–138 checklists 43–44 lung transplantation and 374
pain 141–145 information and communication post heart transplantation 318–319
sedation 138–141 technologies 44–49 renal failure
sleep 145–149 clinical information systems 44–48 acute see acute renal failure
psychological function, measurement of 60–61, computerised order entry and decision chronic 784
60t support 48 oliguric 787